The May 2018 issue of Pharmafocus is now live!
pharmafile | April 23, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â BMS, MSD, Pharmafocus, Shire, Takeda, flypharma, keytruda, mhealth, mobile health summit, opdivo, pharma, sugar taxÂ
Just in time for the first good weather of the year, the May 2018 edition of Pharmafocus is available to read online now!
The Takeda-Shire saga continues as the Japanese pharma firm fires a volley of massive offers at the rare disease specialist. Shire has so far remained uninterested with the $60 billion+ valuations, and some have even read its decision earlier in the month to jettison its oncology unit for $2.4 billion as a move to discourage a potential buyout. The ongoing tale has captivated the industry as we wait to see how it will end – you can read the full story on our front page.
It was a very eventful month for MSD’s immune-oncology drug Keytruda, which quickly followed up a failure in skin cancer as a combo therapy with rousing successes in lung cancer and skin cancer as a monotherapy. The strong data revealed means that the drug is now even better poised to take the lead in its battle with Bristol-Myers Squibb’s Opdivo. You can read more on page 8.
FlyPharma Europe is due to touch down in Brussels for its fourth year in June, bringing together a wide range of industry professionals to address the key issues affecting the pharmaceutical supply chain. You can find all the details and an interview with MSD’s Director of Supply Chain Management, EMEA, Ruud van der Geer, in our event preview on page 13.
We also have full-length features into the impact of Brexit on clinical trials should the UK fail to fully align itself within the EU regulatory framework, and the challenges that are holding back the potential of patient-reported outcomes in today’s healthcare environment.
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …
